Chief Adviser of the Interim Government Muhammad Yunus has convened an emergency meeting at 7:30pm this evening (4 April) at the State Guest House Jamuna to discuss the US tariff issue.

Context will present data highlighting the selection of the first-in-human dose of CT-95, using the minimal anticipated biological effect level (“MABEL”) approach, as required for immune agonist drugs ...

I think combination therapy is coming; it’s just a question of which combinations,’ says Arthur Kavanaugh, MD.

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety and efficacy findings. Bimekizumab, the first IL-17 A and F inhibitor ...

today announced that an abstract highlighting data supporting the immune component of amezalpat’s purported mechanism of action has been accepted for poster presentation at the 2025 American ...

With one month left to voice concerns about the Anne Arundel County Public Schools’ initial redistricting ideas, parents and ...

"AACR is one of the most important oncology meetings in the world, and we are excited to highlight our highly differentiated portfolio of next-generation monovalent targeted protein degraders." ...

H. Lundbeck A/S (Lundbeck) will present positive interim results from the open-label extension of the PACIFIC trial investigating ...

The weight of evidence of these data supports the safety of the proposed clinical starting dose of 0.1 μg/kg for CT-95. CT-95 is a MSLN x CD3 TCE that is intended to redirect T-cell-mediated ...

EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T ...